Commissioned by Norgine Pharmaceuticals Ltd

Information intended for healthcare professionals. This formulary decision guide was developed from content provided by Norgine Pharmaceuticals Ltd in a format developed by Guidelines in Practice.

Click here to download the formulary decision guide (UK/PLV/1017/0031, November 2017).

View the prescribing information for PLENVU®.
View the prescribing information for MOVIPREP® (PEG 3350, sodium sulfate, ascorbic acid, sodium ascorbate, sodium chloride, potassium chloride)

If the PDF does not load within 5 seconds, please refresh the page.

PLENVU, MOVIPREP, NORGINE and the sail logo are registered trademarks of the Norgine group of companies.

UK/PLV/1017/0032aDate of preparation: February 2018